No abstract

Combination formulation of CDP/BPO and ADA were shown to be both effective in decreasing total, inflammatory, and non-inflammatory lesion counts along with well tolerability in Asian patients with mild to moderate acne vulgaris.

8 Breneman D, Bronsky EA, Bruce S et al. Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebocontrolled, comparative trial. J Am Acad Dermatol 1995; 33 (2 pt 1):192-8. 9 Kocatürk E, Kavala M, Kural E et al. Autologous serum skin test vs autologous plasma skin test in patients with chronic urticaria: evaluation of reproducibility, sensitivity and specificity and relationship with disease activity, quality of life and anti-thyroid antibodies. Eur J Dermatol 2011; 21:339-43. 10 Godse KV. Autologous serum skin test at various dilutions. Indian J Dermatol 2011; 56:352-3.B.I. and E.G. contributed equally to this work.

In psoriasis, tazarotene acts by modulating the three main pathogenic features: abnormal differentiation, hyperproliferation of keratinocytes, and inflammation. 3 As with other topical retinoids, adverse events with tazarotene are limited to local effects, most frequently being erythema, pruritus, burning/stinging and, rarely, pyogenic granuloma in patients with psoriasis. 4 However, retinoids are not known to cause depigmentation. Topical use of retinoic acid (RA) produces improvement in hyperpigmentation by reducing the number of functioning melanocytes and/or in inhibiting their ability to synthesize melanin. 5 Retinoids are potent inhibitors of mammalian GSTs (glutathione-s-transferase) and this makes cells more susceptible to the cytotoxic effects of chemicals. 6 We do not have the exact explanation for this observation besides the above-mentioned biochemical mechanisms or the local irritation and erythema following tazarotene causing depigmentation by Koebnerization. The occurrence of vitiligo within an area treated with tazarotene does not illustrate definite direct cause but probably does indicate the need for vigilance to see whether this association occurs again. Clinicians should be aware of potential pigmentary changes, particularly when using tazarotene on areas of skin that are readily visible or in patients of vitiligo for treatment of other dermatoses. We suggest that this rare but important observation should be considered as a potential side-effect of tazarotene. Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol 1998; 39: S129-S133. 4 Weinstein GD, Krueger GG, Lowe NJ et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis. vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997; 37: 85-92. 5 Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975; 111: 40-48. 6 Kasraee B, Handjani F, Aslani FS. Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection? Dermatology 2003; 206: 289-291.